viruses , for preclinical studies . Testing the vaccine candidate against this known virus , with accepted correlates of protection , will help to assess the concepts behind this new technology . This funding forms part of CEPI ’ s programme to support novel RNA vaccine platform technologies for emerging and select endemic infectious diseases , which could offer substantial advantages over existing mRNA technologies , such as multivalency , improved immunogenicity , storage and stability , productivity , response time , and cost-of-goods .
Parexel collaborates with Partex to leverage AI & Big Data for accelerating drug discovery
Parexel , one of the world ’ s largest clinical research organizations ( CROs ), and Partex , the first Data to- Drugs pharma platform , have announced a preferred strategic alliance designed to leverage artificial intelligence ( AI ) -powered solutions to accelerate drug discovery and development for biopharmaceutical customers worldwide and de-risk the assets in their portfolios . Parexel ’ s extensive global expertise across Phase I to IV clinical development combined with Partex ’ s big data and AI capabilities is expected to further advance the efforts of drug developers working to understand the probability of clinical success of assets in their portfolio and recommend other disease indications for which their assets may be clinically viable .
Under the alliance , clinical trial execution by the Partex group of companies will be managed by Parexel as the preferred CRO provider . Parties will also collaborate on improving clinical trial execution for customers through the Partex-validated AI platform , adding to and expanding Parexel ’ s existing AI tools and capabilities .
BioTech
Sanofi India registers 12 % growth in operating profits in Q2 of FY 23-24
Sanofi India Limited has declared its financial results for the quarter and half year ended on June 30th , 2023 . The company has delivered revenue growth of 2 % for the quarter ended 30th June 2023 on a comparable basis and 12 % growth in operating profits , despite the negative impact of the revised pricing for
BIOVOICENEWS . COM 39